Opaleye Management Inc. Raises Stock Position in Disc Medicine, Inc. $IRON

Key Points

• Opaleye Management more than doubled its Disc Medicine stake in the second quarter, adding 434,000 shares to own 855,000 shares worth approximately $62.5 million. Institutional investors collectively own 83.7% of the company.
• Disc Medicine insiders have recently been net sellers, including the CEO and a director; insiders sold 209,797 shares worth about $15.9 million over the past three months.
• The stock opened at $74.14, while analysts maintain a generally positive outlook with a “Moderate Buy” consensus and an average price target of $109.55. However, the company remains a clinical-stage biotech, and its investigational programs face clinical, regulatory, financing, and commercialization risks.

Opaleye Management Inc. raised its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 103.1% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 855,000 shares of the company's stock after acquiring an additional 434,000 shares during the quarter. Disc Medicine comprises approximately 5.7% of Opaleye Management Inc.'s holdings, making the stock its 4th largest position. Opaleye Management Inc. owned about 22.29% of Disc Medicine worth $62,535,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. California State Teachers Retirement System raised its holdings in shares of Disc Medicine by 8,273.0% during the 2nd quarter. California State Teachers Retirement System now owns 2,878,790 shares of the company's stock valued at $210,555,000 after purchasing an additional 2,844,408 shares in the last quarter. BlackRock Inc. acquired a new position in Disc Medicine during the second quarter worth $180,502,000. RA Capital Management L.P. increased its position in Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock worth $156,925,000 after buying an additional 399,026 shares during the last quarter. Wellington Management Group LLP raised its holdings in Disc Medicine by 0.3% during the second quarter. Wellington Management Group LLP now owns 1,741,351 shares of the company's stock valued at $127,362,000 after buying an additional 5,975 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock valued at $134,839,000 after buying an additional 371,576 shares in the last quarter. 83.70% of the stock is owned by institutional investors.

Insider Transactions at Disc Medicine

In other Disc Medicine news, CEO John D. Quisel sold 34,000 shares of the firm's stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $70.21, for a total value of $2,387,140.00. Following the completion of the sale, the chief executive officer owned 226,064 shares in the company, valued at approximately $15,871,953.44. This trade represents a 13.07% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kevin Bitterman sold 49,164 shares of Disc Medicine stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $80.17, for a total value of $3,941,477.88. Following the sale, the director directly owned 13,499 shares in the company, valued at $1,082,214.83. The trade was a 78.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 209,797 shares of company stock valued at $15,934,791. 3.76% of the stock is currently owned by insiders.

Disc Medicine Price Performance

NASDAQ:IRON opened at $74.14 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.14 and a quick ratio of 24.14. Disc Medicine, Inc. has a one year low of $40.00 and a one year high of $99.50. The company has a fifty day moving average price of $77.92 and a 200 day moving average price of $70.85. The stock has a market cap of $2.85 billion, a P/E ratio of -11.27 and a beta of 0.97.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.17. Analysts anticipate that Disc Medicine, Inc. will post -6.61 earnings per share for the current year.

Disc Medicine News Summary

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Positive Phase 2 RESTORE-PV results: DISC-3405 increased hepcidin, lowered serum iron, maintained hematocrit below 45%, improved symptoms, and substantially reduced phlebotomy needs in patients with polycythemia vera. Among 13 patients completing 26 weeks, average phlebotomies fell from 4.0 to 0.6, while 61.5% remained phlebotomy-free. The drug was generally well tolerated. Disc Medicine Reports Positive Phase 2 RESTORE-PV Data
• Positive Sentiment: Analyst support strengthened: Wedbush reaffirmed its “outperform” rating and raised or maintained a $100 price target, implying meaningful upside from recent trading levels. Other firms, including Morgan Stanley, Cantor Fitzgerald, BMO Capital Markets, and Jefferies, also maintain positive ratings. Benzinga analyst report
• Positive Sentiment: Disc Medicine also highlighted positive data from its RALLY-MF trial of selcodebart in myelofibrosis anemia and expects additional program updates by year-end, supporting the broader pipeline narrative. Disc Medicine Presents RESTORE-PV Results
• Neutral Sentiment: Reported short interest was zero shares, indicating no meaningful evidence of short-covering or bearish short positioning. The figure may reflect incomplete or anomalous data.
• Negative Sentiment: Director Kevin Bitterman sold 1,689 shares for approximately $135,000 under a pre-arranged Rule 10b5-1 plan. While scheduled selling reduces its signal, broader recent insider activity has consisted entirely of sales. Kevin Bitterman Insider Sale
• Negative Sentiment: A law firm announced an investigation into potential securities claims involving allegedly misleading company disclosures. This is only an allegation, but it adds headline and litigation risk. Disc Medicine Investor Investigation
• Negative Sentiment: DISC-3405 remains investigational, and the RESTORE-PV study involved only 40 participants. Investors still face clinical, regulatory, financing, and commercialization risks before the results can translate into revenue.

Wall Street Analysts Forecast Growth

Several brokerages have commented on IRON. Wall Street Zen downgraded Disc Medicine from a "hold" rating to a "sell" rating in a report on Saturday, August 29th. BMO Capital Markets restated an "outperform" rating on shares of Disc Medicine in a research note on Thursday. Wedbush reaffirmed an "outperform" rating and set a $100.00 price objective on shares of Disc Medicine in a report on Thursday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Disc Medicine in a report on Tuesday, September 1st. Finally, HC Wainwright reissued a "buy" rating and set a $120.00 target price on shares of Disc Medicine in a research report on Thursday. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $109.55.

About Disc Medicine

Disc Medicine, Inc NASDAQ: IRON is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.